Docetaxel facilitates endothelial dysfunction through oxidative stress via modulation of protein kinase C beta: The protective effects of sotrastaurin

研究成果: Article

11 引文 (Scopus)

摘要

Docetaxel (DTX), a taxane drug, has widely been used as an anticancer or antiangiogenesis drug. However, DTX caused side effects, such as vessel damage and phlebitis, which may reduce its clinical therapeutic efficacy. The molecular mechanisms of DTX that cause endothelial dysfunction remain unclear. The aim of this study as to validate the probable mechanisms of DTX-induced endothelial dysfunction in endothelial cells. Human umbilical vein endothelial cells (HUVECs) were stimulated with DTX (2.5, 5, and 10nM) for 24h to induce endothelial dysfunction. Stimulation with DTX reduced cell viability in a concentration- and time-dependent manner. DTX upregulated caspase-3 activity and TUNEL-positive cells. DTX treatment also increased PKCβ phosphorylation levels and NADPH oxidase activity, which resulted in ROS formation. However, all of these findings were reversed by PKCβ inhibition and NADPH oxidase repression. Finally, we demonstrated that sotrastaurin (AEB-071), a new PKCβ inhibitor, mitigated DTX-induced oxidative injury in endothelial cells. Our findings from this study provide a probable molecular mechanism of DTX-induced oxidative injury in endothelial cells and a new clinical and therapeutic approach for preventing DTX-mediated vessel injury.

原文English
文章編號kfv017
頁(從 - 到)59-67
頁數9
期刊Toxicological Sciences
145
發行號1
DOIs
出版狀態Published - 2015 五月 1

指紋

docetaxel
Protein Kinase C beta
Oxidative stress
Oxidative Stress
Modulation
Endothelial cells
Endothelial Cells
NADPH Oxidase
Wounds and Injuries
sotrastaurin
Cells
Phlebitis
Phosphorylation

All Science Journal Classification (ASJC) codes

  • Toxicology

引用此文

@article{7d8e58df2b5b4015866ed4b75e826c1b,
title = "Docetaxel facilitates endothelial dysfunction through oxidative stress via modulation of protein kinase C beta: The protective effects of sotrastaurin",
abstract = "Docetaxel (DTX), a taxane drug, has widely been used as an anticancer or antiangiogenesis drug. However, DTX caused side effects, such as vessel damage and phlebitis, which may reduce its clinical therapeutic efficacy. The molecular mechanisms of DTX that cause endothelial dysfunction remain unclear. The aim of this study as to validate the probable mechanisms of DTX-induced endothelial dysfunction in endothelial cells. Human umbilical vein endothelial cells (HUVECs) were stimulated with DTX (2.5, 5, and 10nM) for 24h to induce endothelial dysfunction. Stimulation with DTX reduced cell viability in a concentration- and time-dependent manner. DTX upregulated caspase-3 activity and TUNEL-positive cells. DTX treatment also increased PKCβ phosphorylation levels and NADPH oxidase activity, which resulted in ROS formation. However, all of these findings were reversed by PKCβ inhibition and NADPH oxidase repression. Finally, we demonstrated that sotrastaurin (AEB-071), a new PKCβ inhibitor, mitigated DTX-induced oxidative injury in endothelial cells. Our findings from this study provide a probable molecular mechanism of DTX-induced oxidative injury in endothelial cells and a new clinical and therapeutic approach for preventing DTX-mediated vessel injury.",
author = "Hung, {Ching Hsia} and Chan, {Shih Hung} and Chu, {Pei Ming} and Tsai, {Kun Ling}",
year = "2015",
month = "5",
day = "1",
doi = "10.1093/toxsci/kfv017",
language = "English",
volume = "145",
pages = "59--67",
journal = "Toxicological Sciences",
issn = "1096-6080",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Docetaxel facilitates endothelial dysfunction through oxidative stress via modulation of protein kinase C beta

T2 - The protective effects of sotrastaurin

AU - Hung, Ching Hsia

AU - Chan, Shih Hung

AU - Chu, Pei Ming

AU - Tsai, Kun Ling

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Docetaxel (DTX), a taxane drug, has widely been used as an anticancer or antiangiogenesis drug. However, DTX caused side effects, such as vessel damage and phlebitis, which may reduce its clinical therapeutic efficacy. The molecular mechanisms of DTX that cause endothelial dysfunction remain unclear. The aim of this study as to validate the probable mechanisms of DTX-induced endothelial dysfunction in endothelial cells. Human umbilical vein endothelial cells (HUVECs) were stimulated with DTX (2.5, 5, and 10nM) for 24h to induce endothelial dysfunction. Stimulation with DTX reduced cell viability in a concentration- and time-dependent manner. DTX upregulated caspase-3 activity and TUNEL-positive cells. DTX treatment also increased PKCβ phosphorylation levels and NADPH oxidase activity, which resulted in ROS formation. However, all of these findings were reversed by PKCβ inhibition and NADPH oxidase repression. Finally, we demonstrated that sotrastaurin (AEB-071), a new PKCβ inhibitor, mitigated DTX-induced oxidative injury in endothelial cells. Our findings from this study provide a probable molecular mechanism of DTX-induced oxidative injury in endothelial cells and a new clinical and therapeutic approach for preventing DTX-mediated vessel injury.

AB - Docetaxel (DTX), a taxane drug, has widely been used as an anticancer or antiangiogenesis drug. However, DTX caused side effects, such as vessel damage and phlebitis, which may reduce its clinical therapeutic efficacy. The molecular mechanisms of DTX that cause endothelial dysfunction remain unclear. The aim of this study as to validate the probable mechanisms of DTX-induced endothelial dysfunction in endothelial cells. Human umbilical vein endothelial cells (HUVECs) were stimulated with DTX (2.5, 5, and 10nM) for 24h to induce endothelial dysfunction. Stimulation with DTX reduced cell viability in a concentration- and time-dependent manner. DTX upregulated caspase-3 activity and TUNEL-positive cells. DTX treatment also increased PKCβ phosphorylation levels and NADPH oxidase activity, which resulted in ROS formation. However, all of these findings were reversed by PKCβ inhibition and NADPH oxidase repression. Finally, we demonstrated that sotrastaurin (AEB-071), a new PKCβ inhibitor, mitigated DTX-induced oxidative injury in endothelial cells. Our findings from this study provide a probable molecular mechanism of DTX-induced oxidative injury in endothelial cells and a new clinical and therapeutic approach for preventing DTX-mediated vessel injury.

UR - http://www.scopus.com/inward/record.url?scp=84929670452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929670452&partnerID=8YFLogxK

U2 - 10.1093/toxsci/kfv017

DO - 10.1093/toxsci/kfv017

M3 - Article

C2 - 25634538

AN - SCOPUS:84929670452

VL - 145

SP - 59

EP - 67

JO - Toxicological Sciences

JF - Toxicological Sciences

SN - 1096-6080

IS - 1

M1 - kfv017

ER -